Investigation Report on China Fat Emulsion Market[2010-2019]

Submitted by: Submitted by

Views: 10

Words: 768

Pages: 4

Category: Science and Technology

Date Submitted: 12/14/2015 11:09 PM

Report This Essay

Investigation Report on China Fat Emulsion Market[2010-2019]

Bharat Book Bureau provides the report, on “Investigation Report on China Fat Emulsion Market[2010-2019] ” The report provides a Scientifically view of The emulsion of soy bean oil, egg phospholipids and glycerin, fat emulsion injection provides essential fatty acids for people who are unable to get nutrition via an oral diet. https://www.bharatbook.com/drugs-market-research-reports-711120/investigation-china-fat-emulsion.html

15th Dec 2015- Mumbai, India: Bharatbook.com announces a report on “Investigation Report on China Fat Emulsion Market[2010-2019] ” The report also Discussed the sales value of fat emulsion in sample hospitals rose from less than CNY 300 million in 2005 to over CNY 900 million in 2014 and CAGR during this period surpassed 14%.

As an emulsion of soy bean oil, egg phospholipids and glycerin, fat emulsion injection provides essential fatty acids for people who are unable to get nutrition via an oral diet.

The concept of fat emulsion dated back to the 1960s when hospitals in advanced countries found soy bean oil with its oleic acid and linoleic acid to be an ideal component of intravenous nutrition for critically ill patients like those who suffer from serious burn or advanced tumor and dyscrasia or those who had car accident or major surgery. Ever since 1961 when Interlipid, a soybean oil fat emulsion injection, was developed by scientists with Fresenius Kabi (Sweden) Co., Ltd, it has remained the best-selling injection. In 1983, Sino-Swed Pharmaceutical Corp. Ltd introduced raw material and patented technology from Fresenius Kabi (Sweden) Co., Ltd to produce Interlipid. In the mid-1980s, such western giants as Fresenius Company developed medium- and long-chain fatty acid injection with fewer adverse effects which was included by the National Health and Family Planning Commission of the People’s Republic of China into the national medicare drug list as early as a decade...